Published in Eur J Clin Pharmacol on June 01, 2012
Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis. Antimicrob Agents Chemother (2014) 0.90
Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective. Can J Infect Dis Med Microbiol (2015) 0.85
Posaconazole Plasma Concentrations on Days Three to Five Predict Steady-State Levels. Antimicrob Agents Chemother (2016) 0.75
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med (2002) 17.04
Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis (2008) 16.51
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med (2007) 10.40
Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med (2007) 7.91
PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed (2005) 6.36
Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med (2007) 5.88
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother (2008) 2.70
Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin Pharmacol Ther (2010) 2.60
Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy (2007) 2.10
Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Pharmacotherapy (2008) 1.79
The changing face of epidemiology of invasive fungal disease in Europe. Mycoses (2009) 1.67
Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults. Antimicrob Agents Chemother (2009) 1.34
Posaconazole therapeutic drug monitoring: a reference laboratory experience. Antimicrob Agents Chemother (2009) 1.31
Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort. J Antimicrob Chemother (2010) 1.28
Effect of varying amounts of a liquid nutritional supplement on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob Agents Chemother (2009) 1.27
Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. Antimicrob Agents Chemother (2009) 1.24
Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica (2008) 1.24
Posaconazole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapy. Antimicrob Agents Chemother (2010) 1.15
Population pharmacokinetics of posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Curr Med Res Opin (2010) 1.11
HPLC analysis of the antifungal agent posaconazole in patients with haematological diseases. Mycoses (2006) 1.06
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection. Antimicrob Agents Chemother (2009) 1.00
Update on the epidemiology and diagnosis of invasive fungal infection. Int J Antimicrob Agents (2008) 0.99
Omeprazole significantly reduces posaconazole serum trough level. Clin Infect Dis (2009) 0.99
Intracellular concentrations of posaconazole in different compartments of peripheral blood. Antimicrob Agents Chemother (2010) 0.97
Posaconazole: a next-generation triazole antifungal. Future Microbiol (2007) 0.93
Therapeutic drug monitoring of posaconazole in hematology patients: experience with a new high-performance liquid chromatography-based method. Antimicrob Agents Chemother (2010) 0.89
Breakthrough invasive fungal infection in an immunocompromised host while on posaconazole prophylaxis: an omission in patient counseling and follow-up. J Oncol Pharm Pract (2008) 0.84
Posaconazole: clinical pharmacokinetics and drug interactions. Mycoses (2011) 0.83
Real-time single-molecule imaging of the infection pathway of an adeno-associated virus. Science (2001) 4.61
Translational control of C/EBPalpha and C/EBPbeta isoform expression. Genes Dev (2000) 4.06
Localization and capacity of proton pumps in roots of intact sunflower plants. Plant Physiol (1984) 3.60
European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3--2009 update. Bone Marrow Transplant (2010) 3.46
Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A (1998) 3.46
Treatment of older patients with mantle-cell lymphoma. N Engl J Med (2012) 3.46
Photosynthetic O2 formation tracked by time-resolved x-ray experiments. Science (2005) 3.35
Gender differences in long-term survival of patients with colorectal cancer. Br J Surg (2001) 3.18
Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood (2000) 2.70
Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood (2001) 2.50
Methylene blue improves the hepatopulmonary syndrome. Ann Intern Med (2000) 2.43
Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia (2006) 2.38
The NF-M transcription factor is related to C/EBP beta and plays a role in signal transduction, differentiation and leukemogenesis of avian myelomonocytic cells. EMBO J (1993) 2.33
Influence of sex, age, body mass index, and smoking on alcohol intake and mortality. BMJ (1994) 2.31
Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother (2006) 2.31
Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat Med (1999) 2.24
Alternative macrophage activation-associated CC-chemokine-1, a novel structural homologue of macrophage inflammatory protein-1 alpha with a Th2-associated expression pattern. J Immunol (1998) 2.17
Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. J Exp Med (1989) 2.15
Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J Cell Biol (1996) 2.14
13C-urea versus 14C-urea breath test: is there still a need for 14C-urea? Nucl Med Commun (1998) 2.06
ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections. Clin Microbiol Infect (2014) 2.06
Crystal structure of MalK, the ATPase subunit of the trehalose/maltose ABC transporter of the archaeon Thermococcus litoralis. EMBO J (2000) 2.05
Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer (2003) 1.99
Molecular cloning of human paxillin, a focal adhesion protein phosphorylated by P210BCR/ABL. J Biol Chem (1995) 1.86
Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. Aliment Pharmacol Ther (2011) 1.85
Intensive care unit stay is prolonged in chronic alcoholic men following tumor resection of the upper digestive tract. Acta Anaesthesiol Scand (1996) 1.85
Psoriasis induced at the injection site of recombinant interferon gamma. Results of immunohistologic investigations. Arch Dermatol (1990) 1.80
Cloning and heterologous expression of a cDNA encoding 1-deoxy-D-xylulose-5-phosphate reductoisomerase of Arabidopsis thaliana. FEBS Lett (1999) 1.79
Prolonged thromboprophylaxis following hip replacement surgery--results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin) Thromb Haemost (1997) 1.73
ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others. Clin Microbiol Infect (2014) 1.70
ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia (2012) 1.68
Plasma 4beta-hydroxycholesterol: an endogenous CYP3A metric? Clin Pharmacol Ther (2009) 1.66
Hepatitis B virus clearance by transplantation of bone marrow from hepatitis B immunised donor. Lancet (1997) 1.63
Noninvasive quantification of brain edema and the space-occupying effect in rat stroke models using magnetic resonance imaging. Stroke (2004) 1.59
Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Aspects of carcinogenesis and prognostic significance. Cancer (1996) 1.56
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect (2012) 1.55
Confocal imaging of glutathione redox potential in living plant cells. J Microsc (2008) 1.54
Autocrine growth induced by kinase type oncogenes in myeloid cells requires AP-1 and NF-M, a myeloid specific, C/EBP-like factor. EMBO J (1992) 1.53
Pharmacogenomics education: International Society of Pharmacogenomics recommendations for medical, pharmaceutical, and health schools deans of education. Pharmacogenomics J (2005) 1.53
High-efficiency transfer of the T cell co-stimulatory molecule B7-2 to lymphoid cells using high-titer recombinant adeno-associated virus vectors. Hum Gene Ther (1995) 1.52
Inflammatory mediators in bronchoalveolar lavage fluid and plasma in leukocytopenic patients with septic shock-induced acute respiratory distress syndrome. Crit Care Med (1998) 1.50
Molecularly cloned simian immunodeficiency virus SIVagm3 is highly divergent from other SIVagm isolates and is biologically active in vitro and in vivo. J Virol (1989) 1.49
Molecular epidemiology of Encephalitozoon cuniculi and first detection of Enterocytozoon bieneusi in faecal samples of pigs. J Eukaryot Microbiol (1996) 1.49
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect (2012) 1.48
Renal function after cardiopulmonary bypass surgery in cyanotic congenital heart disease. Int J Cardiol (2000) 1.47
Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol Ther (2001) 1.47
IL-9 and IL-13 production by activated mast cells is strongly enhanced in the presence of lipopolysaccharide: NF-kappa B is decisively involved in the expression of IL-9. J Immunol (2001) 1.46
[Clinical research in orthopaedics--creation of a clinical trial unit in orthopaedics/trauma surgery]. Z Orthop Unfall (2010) 1.45
Long-term results after video-assisted thoracoscopic surgery for first-time and recurrent spontaneous pneumothorax. Ann Thorac Surg (2000) 1.45
Hepatocellular carcinoma in Central Europe: prognostic features and survival. Gut (2001) 1.45
Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest (2007) 1.45
Differences in angiogenic potential of classically vs alternatively activated macrophages. Immunobiology (1997) 1.44
Engagement of the T-cell receptor during positive selection in the thymus down-regulates RAG-1 expression. Proc Natl Acad Sci U S A (1992) 1.43
Upper keratinocytes of psoriatic skin lesions express high levels of NAP-1/IL-8 mRNA in situ. J Invest Dermatol (1991) 1.43
Functions of cyclin A1 in the cell cycle and its interactions with transcription factor E2F-1 and the Rb family of proteins. Mol Cell Biol (1999) 1.43
Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2011) 1.42
ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome. Leukemia (2012) 1.42
Incorporation of 1-deoxy-D-xylulose into isoprene and phytol by higher plants and algae. FEBS Lett (1997) 1.42
Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. Br J Cancer (2010) 1.42
Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) treatment. Blood (2001) 1.41
Development of a new G-CSF product based on biosimilarity assessment. Ann Oncol (2009) 1.41
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin Microbiol Infect (2012) 1.41
[Vaccination against rabies: how and when?]. Dtsch Med Wochenschr (2012) 1.41
Loss and degradation of enzyme-bound heme induced by cellular nitric oxide synthesis. J Biol Chem (1995) 1.41
Beta-carbolines in chronic alcoholics following trauma. Addict Biol (1996) 1.40
Large-scale clustering of cDNA-fingerprinting data. Genome Res (1999) 1.40
Hepatopulmonary syndrome: prevalence and predictive value of various cut offs for arterial oxygenation and their clinical consequences. Gut (2002) 1.40
[62-year-old patient with chronic lymphatic leukaemia and persistent fever in chemotherapy induced bone marrow aplasia. Angioinvasive aspergillosis]. Dtsch Med Wochenschr (2011) 1.39
[Psychiatrists who took shelter in French-speaking Switzerland from 1933-1945]. Rev Med Suisse Romande (1992) 1.39
Plasma atrial natriuretic factor in cirrhotic patients with ascites. Effect of peritoneovenous shunt implantation. Gastroenterology (1988) 1.39
Hematopoietic-specific expression of MEFV, the gene mutated in familial Mediterranean fever, and subcellular localization of its corresponding protein, pyrin. Blood (2000) 1.38
Severe pulmonary hypertension reversed by antibiotics in a patient with Whipple's disease. Thorax (1997) 1.38
Human peritoneal mesothelial cells synthesize interleukin-6: induction by IL-1 beta and TNF alpha. Kidney Int (1993) 1.37
ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi. Clin Microbiol Infect (2014) 1.36
Isolation of atypical mycobacteria from tap water in hospitals and homes: is this a possible source of disseminated MAC infection in AIDS patients? J Infect (1995) 1.36
Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells. Cancer Res (1996) 1.36
Pharmacokinetics and pharmacodynamics of moist inhalation epinephrine using a mobile inhaler. Eur J Clin Pharmacol (2013) 1.35
Localization and organization of phenol degradation genes of Pseudomonas putida strain H. Mol Gen Genet (1995) 1.33
Pharmacokinetics of inhaled anaesthetics in a clinical setting: comparison of desflurane, isoflurane and sevoflurane. Br J Anaesth (2000) 1.33
The transposable elements resident on the plasmids of Pseudomonas putida strain H, Tn5501 and Tn5502, are cryptic transposons of the Tn3 family. Mol Gen Genet (1998) 1.33
Shc phosphorylation in myeloid cells is regulated by granulocyte macrophage colony-stimulating factor, interleukin-3, and steel factor and is constitutively increased by p210BCR/ABL. J Biol Chem (1994) 1.33
Important role of nondiagnostic blood loss and blunted erythropoietic response in the anemia of medical intensive care patients. Crit Care Med (1999) 1.32
Forty-one recent cases of invasive zygomycosis from a global clinical registry. J Antimicrob Chemother (2009) 1.31
Initial experience with technetium-99m HM-PAO brain SPECT. J Nucl Med (1987) 1.30
Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines. Blood (2000) 1.29
Distribution of the mevalonate and glyceraldehyde phosphate/pyruvate pathways for isoprenoid biosynthesis in unicellular algae and the cyanobacterium Synechocystis PCC 6714. Biochem J (1998) 1.29
Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort. J Antimicrob Chemother (2010) 1.28
Beta-galactoside-binding protein secreted by activated T cells inhibits antigen-induced proliferation of T cells. Eur J Immunol (1998) 1.27
Differential inhibition of HLA-D- or SB-directed secondary lymphoproliferative responses with monoclonal antibodies detecting human Ia-like determinants. J Immunol (1982) 1.27
Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study. Leukemia (2012) 1.27
Targeting lipid metabolism by the lipoprotein lipase inhibitor orlistat results in apoptosis of B-cell chronic lymphocytic leukemia cells. Leukemia (2007) 1.25